Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on infection[1][2].
Suptavumab 抑制 RSV 与细胞融合[2]。
[1]. SimÕes EAF, et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis. 2021 Dec 6;73(11):e4400-e4408.
[2]. Rodriguez-Fernandez R, et al. Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection. Pediatr Infect Dis J. 2021 May 1;40(5S):S35-S39.
















